Boehringer Ingelheim International Gmbh

Zealand Pharma A/s

Ajinomoto Co., Ltd.

Boehringer Ingelheim Pharma Gmbh & Co Kg

Boehringer Ingelheim Pharma Kg

Dr. Karl Thomae Gmbh

Leo Thomas

Frank Himmelsbach

Matthias Eckhardt

Peter Eickelmann

Elke Langkopf

Mohammad Tadayyon

Thorsten Lehmann-Lintz

Michael Mark

Edward Leon Barsoumian

Achim Sauer

Armin Heckel

Dirk Stenkamp

Dieter Wolfgang Hamprecht

Ditte Riber

Jakob Lind Tolborg

Marcus Schindler

Klaus Rudolf

Norbert Hauel

Philipp Lustenberger

Stephan Georg Mueller

Gerald Juergen Roth

Dieter Wiedenmayer

Juergen Prestle

Joerg Kley

Wesley Peter Blackaby

Ian Linney

Iris Kauffmann-Hefner

Klaus Dugi

Norbert Redemann

Ralf R H Lotz

Wolfgang Rist

Rasmus Just

Keld Fosgerau

Matthias Austen

Pia Nørregaard

Kay Schreiter

Martin Schneider

Robert Augustin

Fei Han

John Danilewicz

Phillip Black

Ralf Lotz

Adil Duran

Gerd Kraemer

Ruediger Streicher

Hans-Juergen Martin

Sarah Low

Rolf Grempler

Gebhard Adelgoss

Leo John Seman

Gebhard Schilcher

Nina Zippel

Steffen Maier

Sabine Pinnetti

Regine Ritter

Sanjaya Singh

Roland Maier

Marco Santagostino

Justin M Scheer

Rajkumar Ganesan

Stefan Scheuerer

Bernd Nosse

Heather Tye

Pankaj Gupta

Thomas Klein

Rachel Rebecca Barrett

Uli Christian Broedl

Gerhard Hallermayer

Bernhard Eisele

Priyanka Gupta

Remko Alexander Bakker

Christofer Siegfried Tautermann

Sathyadevi Venkataramani

Peter Muller

Ralph-Michael Budzinski

Alexander Heifetz

Peter Michael Benz

Sandeep Kumar

Helen Haixia Wu

Rudolph Hurnaus

Marina Kristina Willwacher

Ferenc Kontes

Dongmei Liu

Gerd Luippold

Holger Fuchs

Kristin Laura Bovat

Stephan-Georg Mueller

Christopher John Brown

Natacha Prevost

Pia Norregard

Heiko Niessen

Pia NØRREGARD

The present invention relates to the medical use of specific long-acting glucagon analogues having dual GLP-1/glucagon receptor agonist activity in the prevention and/or treatment of metabolic liver disease, particularly non-alcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), NAFLD-associated liver fibrosis and/or cirrhosis.

Glucagon analogues as long-acting GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis

The invention relates to a pharmaceutical composition comprising an SGLT2 inhibitor, a DPPIV inhibitor and a third antidiabetic agent which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.

Pharmaceutical composition, methods for treating and uses thereof

This invention relates to binding molecules that bind specifically Vascular Endothelial Growth Factor (VEGF) and Tropomyosin receptor kinase B (TrkB) and their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of diseases of the eye.

Bispecific anti-VEGF and anti-TrkB binding molecules for the treatment of eye diseases

The invention relates to cyclopentathiophene carboxamides of formula (I.0) wherein R, R, R, R, and n are as defined herein, and pharmaceutically acceptable salts thereof. The invention also relates to the use of the cyclopentathiophene carboxamides of formula (I.0) for the treatment of diseases which can be influenced by antagonizing the activity mediated by the platelet activating factor receptor.

Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists

Disclosed are antibodies and fragments thereof that target the A-domain of Neuropilin-1 (Nrp1A). Also disclosed are methods of using the anti-Nrp1A antibodies for the treatment of various diseases or disorders.

Anti-NRP1A antibodies and their uses for treating eye or ocular diseases

The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

Acylated glucagon analogue

The present invention relates to antibodies and fragments thereof that target semaphorin 3A (Sema3A). More specifically, anti-Sema3A antibodies and methods of use for the treatment of various diseases or disorders are disclosed.

Anti-Sema3A antibodies and their uses for treating eye or ocular diseases

The invention relates to a pharmaceutical composition according to the claimcomprising an SGLT2 inhibitor, a DPPIV inhibitor and a third antidiabetic agent which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.

The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

Glucagon analogues

The present invention relates to compounds defined by formula I wherein the groups X, Y, W and Rto Rare defined as in claim, possessing valuable pharmacological activity. Particularly the compounds are agonists of the 5-HT2C receptor, and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this receptor, such as metabolic and CNS-related disorders.

6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them

The present invention relates to methods for treating and/or preventing metabolic diseases comprising the combined administration of a DPP-4 inhibitor and a long-acting insulin. The invention further relates to a DPP-4 inhibitor for subcutaneous or transdermal use.

Diabetes therapy

Growing community of inventors

Biberach, Germany

Leo Thomas